Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Optical imaging of metabolism in HER2 overexpressing breast cancer cells.

Walsh A, Cook RS, Rexer B, Arteaga CL, Skala MC.

Biomed Opt Express. 2012 Jan 1;3(1):75-85. doi: 10.1364/BOE.3.000075. Epub 2011 Dec 9.

2.

Optical redox ratio differentiates breast cancer cell lines based on estrogen receptor status.

Ostrander JH, McMahon CM, Lem S, Millon SR, Brown JQ, Seewaldt VL, Ramanujam N.

Cancer Res. 2010 Jun 1;70(11):4759-66. doi: 10.1158/0008-5472.CAN-09-2572. Epub 2010 May 11.

3.

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R.

Breast Cancer Res. 2011;13(6):R121. doi: 10.1186/bcr3067. Epub 2011 Nov 28.

4.

Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.

Fan P, McDaniel RE, Kim HR, Clagett D, Haddad B, Jordan VC.

Eur J Cancer. 2012 Dec;48(18):3488-98. doi: 10.1016/j.ejca.2012.04.020. Epub 2012 Jun 2.

5.

Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.

Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad ME, Sevick-Muraca EM.

J Nucl Med. 2007 Sep;48(9):1501-10.

6.

Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.

Chen AC, Migliaccio I, Rimawi M, Lopez-Tarruella S, Creighton CJ, Massarweh S, Huang C, Wang YC, Batra SK, Gutierrez MC, Osborne CK, Schiff R.

Breast Cancer Res Treat. 2012 Jul;134(2):583-93. doi: 10.1007/s10549-012-2082-9. Epub 2012 May 29.

7.

Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma.

Ropero S, Menéndez JA, Vázquez-Martín A, Montero S, Cortés-Funes H, Colomer R.

Breast Cancer Res Treat. 2004 Jul;86(2):125-37.

PMID:
15319565
8.

Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy.

Gee MS, Upadhyay R, Bergquist H, Alencar H, Reynolds F, Maricevich M, Weissleder R, Josephson L, Mahmood U.

Radiology. 2008 Sep;248(3):925-35. doi: 10.1148/radiol.2482071496. Epub 2008 Jul 22.

10.

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.

García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J.

Eur J Cancer. 2014 Oct;50(15):2725-34. doi: 10.1016/j.ejca.2014.07.004. Epub 2014 Aug 12.

PMID:
25128455
11.

Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.

Bilir B, Kucuk O, Moreno CS.

J Transl Med. 2013 Nov 4;11:280. doi: 10.1186/1479-5876-11-280.

12.

Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.

Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J.

Cancer. 2010 Sep 15;116(18):4227-37. doi: 10.1002/cncr.25309.

13.

Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response.

Lazaro G, Smith C, Goddard L, Jordan N, McClelland R, Barrett-Lee P, Nicholson RI, Hiscox S.

Endocr Relat Cancer. 2013 Aug 28;20(5):691-704. doi: 10.1530/ERC-13-0019. Print 2013 Oct.

14.
16.

Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer.

Collins DC, Cocchiglia S, Tibbitts P, Solon G, Bane FT, McBryan J, Treumann A, Eustace A, Hennessy B, Hill AD, Young LS.

Oncogene. 2015 Jan 22;34(4):525-30. doi: 10.1038/onc.2013.586. Epub 2014 Jan 27.

PMID:
24469058
18.

Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance.

Emde A, Mahlknecht G, Maslak K, Ribba B, Sela M, Possinger K, Yarden Y.

Transl Oncol. 2011 Oct;4(5):293-300. Epub 2011 Oct 1.

19.

Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations.

Koay DC, Zerillo C, Narayan M, Harris LN, DiGiovanna MP.

Breast Cancer Res. 2010;12(4):R62. doi: 10.1186/bcr2625. Epub 2010 Aug 9.

20.

Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.

Joshi JP, Brown NE, Griner SE, Nahta R.

Biochem Pharmacol. 2011 Nov 1;82(9):1090-9. doi: 10.1016/j.bcp.2011.07.082. Epub 2011 Jul 23.

Supplemental Content

Support Center